Evan Guillemin

Evan Guillemin (chief executive) discloses dealings in Mesa Laboratories Inc /CO/ to SEC (Form 4). The record holds 51 filings, for trades running from 30 December 2009 to 1 September 2022.

On the open market, the record shows 4 purchases worth €1.7M and 19 sales worth €9.2M. Sales outweigh purchases by €7.4M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 2 share grants and 23 option exercises. Since January 2022: no purchases and 1 sale on the market.

In size, the median ticket on the buying side is €393k. Looking at 4 purchases old enough to measure, the stock rose over the following 90 days in 25% of cases; the median change was -1.2%. Past outcomes like these are no guarantee of what comes next.

Most recently, on 2 September 2022, the filings show an option exercise in Mesa Laboratories Inc /CO/. The last purchase on record was published on 3 March 2011, which is 5,729 days ago. The median gap between a trade and its publication by SEC (Form 4) is 1 day. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.